Investor List:

Top Therapeutics Series B Investors in San Francisco Bay Area (14)

Know someone who's actively diligencing and investing? Add them to this list.
About this list
We’ve compiled a list of the top Therapeutics investors. The goal is to help Founders find the best investors to target and get introduced to.
Photo of Geoffrey Smith, Managing Partner at Digitalis Ventures
Geoffrey Smith
Digitalis Ventures·Managing Partner
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in New York (NY), Investors in Los Angeles (CA), Investors in San Francisco (CA), Investors in Boston (MA)
Investors in BioTech (Series B), Investors in BioTech (Seed), Investors in Manufacturing (Series B), Investors in BioTech (Series A), Investors in Manufacturing (Seed), Investors in Manufacturing (Series A), Investors in Health IT (Series A), Investors in Health & Hospital Services (Series B), Investors in BioTech (Seed), Investors in BioTech (Seed), Investors in BioTech (Seed), Investors in Los Angeles / Southern California (Other Lists), Investors in BioTech (Seed), Investors in New York City (Other Lists), Investors in Health IT (Seed), Investors in Health IT (Seed), Investors in Health IT (Seed), Investors in Health & Hospital Services (Series A), Investors in Health & Hospital Services (Seed), Investors in San Francisco Bay Area (Other Lists), Investors in Health & Hospital Services (Seed), Investors in Manufacturing (Seed), Investors in Health & Hospital Services (Seed), Investors in Health & Hospital Services (Seed), Investors in Manufacturing (Seed), Investors in Manufacturing (Seed), Investors in BioTech (Series A), Investors in BioTech (Series A), Investors in Manufacturing (Seed), Investors in BioTech (Series A), Investors in BioTech (Series A), Investors in Health IT (Series A), Investors in Health IT (Series A), Investors in Health IT (Series A), Investors in Health IT (Series A), Investors in Health & Hospital Services (Series A), Investors in Manufacturing (Series A), Investors in Health & Hospital Services (Series A), Investors in Health & Hospital Services (Series A), Investors in Manufacturing (Series A), Investors in BioTech (Series B), Investors in Manufacturing (Series A), Investors in Health & Hospital Services (Series A), Investors in BioTech (Series B), Investors in Manufacturing (Series A), Investors in BioTech (Series B), Investors in Health IT (Series B), Investors in BioTech (Series B), Investors in Health IT (Series B), Investors in Health IT (Series B), Investors in Manufacturing (Series B), Investors in Health IT (Series B), Investors in Manufacturing (Series B), Investors in Health & Hospital Services (Series B), Investors in Health & Hospital Services (Series B), Investors in Manufacturing (Series B), Investors in Health & Hospital Services (Series B), Investors in Health & Hospital Services (Series B), Investors in Manufacturing (Series B), Investors in Boston / New England (Other Lists), Investors in Diagnostics (Series A), Investors in Diagnostics (Series A), Investors in Digital Health (Seed), Investors in Digital Health (Series B), Investors in Diagnostics (Seed), Investors in Digital Health (Series B), Investors in Diagnostics (Series B), Investors in Diagnostics (Series A), Investors in Diagnostics (Series B), Investors in Digital Health (Series A), Investors in Diagnostics (Seed), Investors in Diagnostics (Series B), Investors in Diagnostics (Series A), Investors in Diagnostics (Seed), Investors in Digital Health (Series A), Investors in Diagnostics (Series B), Investors in Digital Health (Seed), Investors in Digital Health (Series B), Investors in Diagnostics (Seed), Investors in Digital Health (Series A), Investors in Digital Health (Series B), Investors in Digital Health (Seed), Investors in Diagnostics (Series B), Investors in Diagnostics (Seed), Investors in Diagnostics (Series A), Investors in Digital Health (Seed), Investors in Digital Health (Series A), Investors in Digital Health (Series B), Investors in Therapeutics (Seed), Investors in Therapeutics (Seed), Investors in Therapeutics (Series A), Investors in Therapeutics (Series A), Investors in Therapeutics (Series A), Investors in Therapeutics (Seed), Investors in Therapeutics (Series B), Investors in Therapeutics (Series A), Investors in Therapeutics (Series B), Investors in Therapeutics (Series A), Investors in Therapeutics (Seed), Investors in Therapeutics (Series B), Investors in Therapeutics (Series B), Investors in Therapeutics (Series B), Investors in Therapeutics (Seed), Investors in Health IT (Seed), Investors in Health IT (Seed), Investors in Health IT (Series B), Investors in Digital Health (Series A), Investors in Digital Health (Seed), Investors in Health & Hospital Services (Seed)
Photo of Eric Weinstein, Managing Director at Thiel Capital
Eric Weinstein
Thiel Capital·Managing Director
Sweet spot: $1.5M
Range: $100K - $1.5M
Investors in San Francisco (CA)
Photo of Dan Becker, Managing Director at Access Biotechnology
Dan Becker
Access Biotechnology·Managing Director
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in San Mateo (CA), Investors in New York (NY)
Investors in Pharmaceuticals (Seed), Investors in BioTech (Series B), Investors in BioTech (Seed), Investors in Pharmaceuticals (Series B), Investors in BioTech (Series A), Investors in Pharmaceuticals (Series A), Investors in BioTech (Seed), Investors in BioTech (Seed), Investors in New York City (Other Lists), Investors in San Francisco Bay Area (Other Lists), Investors in Pharmaceuticals (Seed), Investors in Pharmaceuticals (Seed), Investors in BioTech (Series A), Investors in BioTech (Series A), Investors in Pharmaceuticals (Series A), Investors in Pharmaceuticals (Series A), Investors in BioTech (Series B), Investors in BioTech (Series B), Investors in Pharmaceuticals (Series B), Investors in Pharmaceuticals (Series B), Investors in Therapeutics (Seed), Investors in Therapeutics (Series A), Investors in Therapeutics (Series A), Investors in Therapeutics (Seed), Investors in Therapeutics (Series B), Investors in Therapeutics (Series B), Investors in Therapeutics (Series B), Investors in Therapeutics (Series A), Investors in Therapeutics (Seed)
Photo of Sangwoo Lee, Managing Director at Korea Investment Partners
Sangwoo Lee
Korea Investment Partners·Managing Director
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in Mountain View (CA)
Investors in Pharmaceuticals (Seed), Investors in BioTech (Series B), Investors in BioTech (Seed), Investors in Pharmaceuticals (Series B), Investors in Pharmaceuticals (Series A), Investors in BioTech (Series A), Investors in BioTech (Seed), Investors in Pharmaceuticals (Seed), Investors in San Francisco Bay Area (Other Lists), Investors in BioTech (Series A), Investors in Pharmaceuticals (Series A), Investors in BioTech (Series B), Investors in Pharmaceuticals (Series B), Investors in Therapeutics (Seed), Investors in Therapeutics (Series A), Investors in Therapeutics (Series B), Investors in Therapeutics (Seed), Investors in Therapeutics (Series B), Investors in Therapeutics (Series A)
Photo of Timothy Van Voris, Managing Director at Thiel Capital
Timothy Van Voris
Thiel Capital·Managing Director
Sweet spot: $1.5M
Range: $100K - $1.5M
Investors in San Francisco (CA)
Photo of David Malek, Stealth Mode Biotech
David Malek
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in San Francisco (CA)
Investors in BioTech (Series B), Investors in BioTech (Seed), Investors in BioTech (Series A), Investors in BioTech (Seed), Investors in San Francisco Bay Area (Other Lists), Investors in BioTech (Series A), Investors in BioTech (Series B), Investors in Therapeutics (Seed), Investors in Therapeutics (Series A), Investors in Therapeutics (Series B), Investors in Therapeutics (Series B), Investors in Therapeutics (Series A), Investors in Therapeutics (Seed)
Photo of Blake Masters, Principal at Thiel Capital
Blake Masters
Thiel Capital·Principal
Sweet spot: $1.5M
Range: $100K - $1.5M
Investors in San Francisco (CA), Investors in Tucson (AZ), Investors in Los Angeles (CA)
Investors in Pharmaceuticals (Seed), Investors in BioTech (Series B), Investors in Manufacturing (Series B), Investors in BioTech (Seed), Investors in Pharmaceuticals (Series B), Investors in Manufacturing (Series A), Investors in Manufacturing (Seed), Investors in Pharmaceuticals (Series A), Investors in Health & Hospital Services (Series B), Investors in BioTech (Series A), Investors in BioTech (Seed), Investors in Los Angeles / Southern California (Other Lists), Investors in BioTech (Seed), Investors in Health & Hospital Services (Series A), Investors in San Francisco Bay Area (Other Lists), Investors in Health & Hospital Services (Seed), Investors in Pharmaceuticals (Seed), Investors in Manufacturing (Seed), Investors in Health & Hospital Services (Seed), Investors in Pharmaceuticals (Seed), Investors in BioTech (Series A), Investors in Manufacturing (Seed), Investors in BioTech (Series A), Investors in Pharmaceuticals (Series A), Investors in Health & Hospital Services (Series A), Investors in Manufacturing (Series A), Investors in Pharmaceuticals (Series A), Investors in Health & Hospital Services (Series A), Investors in BioTech (Series B), Investors in Manufacturing (Series A), Investors in BioTech (Series B), Investors in Manufacturing (Series B), Investors in Pharmaceuticals (Series B), Investors in Pharmaceuticals (Series B), Investors in Health & Hospital Services (Series B), Investors in Health & Hospital Services (Series B), Investors in Manufacturing (Series B), Investors in Therapeutics (Seed), Investors in Therapeutics (Seed), Investors in Therapeutics (Series A), Investors in Therapeutics (Series A), Investors in Therapeutics (Series B), Investors in Therapeutics (Series B), Investors in Therapeutics (Series B), Investors in Therapeutics (Series A), Investors in Therapeutics (Seed), Investors in Health & Hospital Services (Seed)
Photo of Carlos Solórzano, Principal at Section 32
Carlos Solórzano
Section 32·Principal
Sweet spot: $25K
Range: $10K - $50K
Investors in SF Bay Area (CA)